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INTRODUCTION 
 
Type 1 Diabetes mellitus is a chronic metabolic syndrome characterized 
by hyperglycemia as a cardinal biochemical feature due to deficient insulin 
secretion. It is the most common endocrine – metabolic disorder of childhood 
and adolescence , with important consequences of physical and emotional 
development. 
      Morbidity and mortality stem from acute metabolic derangements and from 
long term complications that affect small and large vessels resulting in 
retinopathy,nephropathy,neuropathy,ischemic heart disease and arterial 
obstruction. 
      Diabetic nephropathy accounts for significant reduction in life expectancy of 
diabetic patients. It is the leading cause of end stage renal disease and accounts 
for 50 % of deaths.The progression of diabetic nephropathy from the 
appearance of clinical proteinuria to end stage renal failure is usually 
irreversible without any intervention. Approximately 80% type 1 diabetic 
patients with persistent microalbuminuria develop overt nephropathy after 10 to 
15 yrs. Eventually 50% of these develop end stage renal disease within 10 yrs 
and 75% by 20 yrs.  
      The earliest detectable change in the course of diabetic nephropathy is the 
thickening in the glomerulus. At this stage ,the kidney may leak more serum 
albumin than normal in the urine and this can be detected by sensitive medical 
tests for albumin. This stage is called microalbuminuria.Hence it is considered 
as an early marker of diabetic nephropathy (Chronic kidney disease).In other 
words, the term microalbuminuria has been used to describe the amount of 
albumin in the urine which is less than that can be detected by ordinary clinical 
tests such as albustix but is otherwise still associated with future 
disease.According to the Gento Monticatini convention , microalbuminuria is 
said to be present when urine albumin excretion rate is 30 to 300 mg/24 hr or 
more than 20 mg/l in a spot sample. This is the incipient stage of diabetic 
nephropathy and it is totally reversible. Once overt proteinuria develops, the 
disease process becomes irreversible. 
       Early medical treatment with ACE inhibitors and lifestyle modification 
have been shown to halt the progress from micro to macroalbuminuria and 
eventually End Stage Renal Disease (ESRD). Therefore detection of 
microalbuminuria as early as possible in the course of disease is very important. 
 
 
REVIEW OF LITERATURE 
Diabetic nephropathy is also known as Kimmelstiel Wilson  syndrome 
and it was discovered in 1936 by Clifford Wilson and Paul Kimmelstiel. 
Diabetic nephropathy occurs as a result of an interaction between hemodynamic 
and metabolic factors(1).  
EPIDEMIOLOGY 
Diabetic nephropathy affects approximately one third of people with type 
1 or type 2 diabetes mellitus. Risk factors affecting progression of kidney 
disease include baseline albumin excretion, age, glycemic control, blood 
pressure, serum cholesterol and use of renin-angiotensin system blockers. As 
the total number of people with diabetes is projected to increase substantially by 
2050, the prevalence of diabetic nephropathy will rise dramatically, with 
concomitant increase in associated cardiovascular mortality and end stage renal 
disease. This will produce significant social and economic ramifications, 
particularly in the developing world. 
Natural History of Diabetic Nephropathy 
The earliest clinical evidence of nephropathy is the  presence of 
microalbuminuria . It occurs in 30%  of type 1 diabetics 5 to 15 years after 
diagnosis but may  be present at diagnosis in type 2 diabetics as the time of 
onset of type 2 diabetes is often unknown. Microalbuminuria progresses to 
proteinuria over the next 7 to 10 years. Once overt proteinuria develops, renal 
function progressively declines and end stage renal disease is reached after 
about 10 years. Hence, the elucidation of molecular pathogenesis of diabetic 
nephropathy is necessary for the development of effective treatment modalities 
to prevent onset of diabetic nephropathy to end stage renal disease (ESRD). 
PATHOPHYSIOLOGY 
Multiple mechanisms contribute to the development and outcomes of 
diabetic nephropathy (microalbuminuria) and these mechanisms are found to be 
similar in both adults and pediatric populations.In this review we have focused 
on the particular factors involved in the pathogenesis of diabetic nephropathy. 
Hemodynamic changes: 
          Under conditions of sustained hyperglycemia, the glomerular cells are 
affected by various mechanisms. These changes lead to altered structure and 
function in the glomerulus(2). In the kidney, the first observed functional change 
is an abnormally increased GFR(3). This change develops before any major 
histological change in the glomerular structure. Later in the development of 
diabetic nephropathy, typical histologically visible changes seen are : thickened 
GBM, diffuse glomerulosclerosis, nodular glomerulosclerosis,  exudative 
lesions in the Bowman’s capsule , podocyte loss(4), glomerular hyperperfusion 
and hyperfiltration(5). 
             The early signs of glomerular hyperperfusion and hyperfiltration result 
from decreased resistance in both the afferent and efferent arterioles of the 
glomerulus. The afferent arteriole seems to have a greater decrease in resistance 
than the efferent. Many factors have been reported to be involved in this 
defective autoregulation including prostanoids, nitric oxide, vascular endothelial 
growth factor VEGF (now known as VEGF-A), TGF-β1 and the renin-
angiotensin system, specifically           angitensin II(6). These cyclic changes in 
glomerular volume lead to recurrent episodes of stretch and relaxation of the 
glomerular structural components, including mesangial cells and podocytes(7,8,9). 
                Mesangial cells, when exposed to continuous cycle of stretch/ 
relaxation, alter their morphology. Specifically, these cells change from their 
normal stellate to a straplike appearance  aligning with their long axis 
perpendicular to the direction of stress(10). This leads to enhanced proliferation 
and increased production of extracellular matrix components. This prosclerotic 
effect of stretch  occurs partly as a result of increase in gene and / or protein 
expression of extracellular matrix components such as collagen I, III and IV, 
fibronectin, and laminin (10-12). 
                 These hemodynamic changes facilitates albumin leakage from the 
glomerular capillaries, overproduction of mesangial cell matrix  as well as 
thickening of the glomerular basement membrane and injury to podocytes. In 
addition, increased mechanical strain resulting from these hemodynamic 
changes can induce localized release of some cytokines and growth factors. 
Mesangial cells are crucial for maintenance of glomerular capillary structure 
and for the modulation of glomerular filtration via smooth-muscle activity. 
Hyperglycemia: 
            Hyperglycemia is associated with an increase in mesangial cell 
proliferation and hypertrophy  as well as increased matrix production and 
basement membrane thickening. In vitro studies have demonstrated that 
hyperglycemia is associated with increased mesangial cell matrix 
production(13,14) and mesangial cell apoptosis(15,16). Mesangial cell expansion 
seems to be mediated in part by an increase in the mesangial cell glucose 
concentration, since similar changes are observed in mesangial glucose milieu 
as  overexpression of glucose transporters such as GLUT 1 and GLUT 4, 
thereby increasing glucose entry into the cells. Hyperglycemia might also 
upregulate VEGF expression in podocytes which could markedly increases 
vascular permeability(17,18). There are four mechanisms that explain how 
hyperglycemia causes tissue damage and diabetic nephropathy: Nonenzymatic 
glycosylation that generates advanced glycosylation end products, activation of 
protein kinase C (PKC), acceleration of the aldose reductase pathway(19,20) 
[Oxidative stress seems to be a theme common to above three pathways(21)] and 
activation of GPR 91 receptor in the kidney(22). 
 
Dyslipidemia: 
                Dyslipidemia has been hypothesized to cause kidney damage and to 
play an important role in the progression of renal failure(23). In animal models, 
hyperlipidemic diets worsen renal injury and lipid-lowering strategies 
ameliorate renal injury(24,25,26,27). Dyslipidemia may damage glomerular capillary 
endothelial and mesangial cells as well as podocytes. Mesangial cells express 
receptors for LDL and oxidized LDL,  which upon activation induce mesangial 
cell proliferation, increase mesangial matrix deposition  and enhance the 
production of chemokines (such as macrophage chemo-attractant protein-1), 
cytokines (such as interleukin 6) or growth factors. Macrophage chemo-
attractant protein-1 enhances the recruitment of macrophages which can 
infiltrate the glomerulus and become foam cells that release cytokines. Oxidized 
LDL increases the adhesion of monocytes to glomerular endothelial cells 
favoring  monocyte infiltration and affects tubular epithelial cells(27). 
Hypercholesterolemia and hypertriglyceridemia are also associated with 
podocyte injury  which secondarily leads to mesangial sclerosis(25). Oxidized 
LDL induces apoptosis of podocytes and nephrin loss (a key component of the 
glomerular filtration barrier) and increases albumin diffusion in podocyte 
monolayers in vitro(28). 
A number of studies have shown an increased association between 
patients with microalbuminuria and abnormalities in serum lipoproteins. These 
lipid abnormalities include a low level of  high density lipoprotein (HDL) as 
well as high values of low density lipoprotein (LDL), total cholesterol, 
triglycerides and increased levels of lipoprotein (a). In a cross-sectional analysis 
of 1160 Type 1 diabetic individuals in the Diabetes Control and Complications 
Trial (DCCT), progressive increases in albuminuria were associated with 
elevations in proatherogenic intermediate density lipoproteins and small dense 
LDL particles(29). In addition, among both diabetic and non-diabetic patients 
with reduced serum HDL cholesterol(30,31,32,33,34), the most consistent association  
between lipoprotein abnormalities and microalbuminuria was with the low 
HDL. This suggests that clearance of LDL cholesterol may be as important as 
lower levels of this lipoprotein subfraction to avoid cellular injury. Thus, the 
apparent association between microalbuminuria and cardiovascular disease  
may be related to this adverse risk factor profile. 
Prorenin: 
 Initial clinical studies in children and adolescents suggest that increased 
plasma prorenin activity is a risk factor for the development of diabetic 
nephropathy(35,36). The prorenin receptor in the kidney is recently identified and 
characterized(37-40). The prorenin receptor in the kidney is located in the 
mesangium as well as podocytes  and its blockade has a beneficial effect on 
kidneys in animal models of diabetes.  
 
Angiogenic And Proinflammatory Factors: 
                Recent studies suggest that an inflammatory mechanism mediated by 
macrophages and angiogenesis may play important roles in the pathogenesis of 
diabetic nephropathy. Relatively recent reports (41-43) described that the degree of 
neovascularization was significantly increased in patients with diabetic 
nephropathy and correlates with the expression of  VEGF and angiopoietin 
which  are likely  to  contribute to diabetic nephropathy by promoting vessel 
leakage and reducing transendothelial electrical resistance. The angiogenic 
growth factor VEGF induces the activation of matrix-degrading protease 
represented by matrix metalloproteases and migration and proliferation of 
endothelial cells(44). Recent animal studies utilizing a neutralizing anti-VEGF 
antibody further demonstrated the involvement of this factor in early glomerular 
hypertrophy and mesangial matrix accumulation in the progressive stage of 
diabetic nephropathy. TGF-β has been recognized as a profibrotic growth factor 
involved in the expansion of mesangial matrix and renal hypertrophy in diabetic 
nephropathy. 
Immunological studies on mechanisms of Diabetic nephropathy: 
           Recently increased levels of inflammatory markers such as C-reactive 
protein and interleukin-6 were found to be present in type 1 diabetic patients 
with micro or macroalbuminuria (45). Other inflammatory cytokines also 
contribute to the development and progression of diabetic nephropathy, 
specifically interleukin-1 (IL-1), IL-8 and tumor necrosis factor. Concentrations 
of all these cytokines were  increased in models of diabetic nephropathy and 
seemed to affect the disease via multiple mechanisms (46). This finding suggests 
that the pathogenetic mechanisms of diabetic nephropathy also involve the 
immunological and  inflammatory process. 
Oxidative Stress: 
 Generally, metabolic activity within the nephron produces a large 
amount of reactive oxygen species that are counter  balanced by a large number 
of antioxidant enzymes and free radical scavenging systems. Reactive oxygen 
species mediate many negative biological effects including peroxidation of cell 
membrane lipids, oxidation of proteins, renal vasoconstriction and damage to 
DNA. Hyperglycemia specifically induces oxidative stress even before diabetes 
becomes clinically apparent. Concentrations of markers of DNA damage 
induced by reactive oxygen species are higher in patients with more  severe 
nephropathy. 
 Endothelial Cell Dysfunction (ECD): 
           Diabetic nephropathy is preceded by glomerular hyperperfusion and 
hyperfiltration which occur early in type1 and in some 15-44% of type 2 
diabetic patients at diagnosis  and  these play a pathogenetic role in ECD, the 
early stage of diabetic nephropathy(47-50). Endothelial cell dysfunction (ECD) is 
therefore defined as decreased synthesis, release, and/ or activity of endothelial-
derived nitric oxide. The pathophysiology of ECD expressed in various degrees 
is emerging as a hallmark of several highly prevalent renal as well as 
cardiovascular diseases and other chronic diabetic complications(51). 
Podocyte Damage And Nephrin Loss: 
             Recent data suggest that the podocytes, the  specialized visceral 
epithelial cells are important for the maintenance of the dynamic functional 
barrier(52)  and the number of podocytes may be reduced in the glomeruli of both 
type1 and type2 diabetic patients(53,54).   Furthermore, it has been reported that 
nephrin, a recently found podocyte protein is crucial for maintaining the 
integrity of the interpodocyte slit membrane structure and for maintenance of an 
intact filtration barrier. In diabetic nephropathy, the protein level of nephrin 
decreases  possibly via loss into the urine due to synthesis of splice variant 
isoforms of the nephrin lacking a transmembrane domain (55,56). 
Genetic Susceptibility : 
             Genotype seems to be an important determinant of both incidence and 
severity of diabetic nephropathy (57-59). The increase in risk cannot be explained 
by the duration of diabetes,  hypertension or the degree of glycemic control. 
Environmental and genetic factors must, therefore have roles in the 
pathogenesis of diabetic nephropathy. In patients with type1 diabetes, the 
likelihood of developing diabetic nephropathy is markedly increased in those 
who have a sibling or parent with diabetic nephropathy(60,61). There is also 
growing evidence that the genetic background determines the risk of 
nephropathy in patients with diabetes. Epidemiologic studies have shown that 
35% of the patients with diabetes develop nephropathy  irrespective of glycemic 
control (62,63). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Symbol Name Locus Rationale 
SLC12A3 Solute carrier family 
12 member (sodium   
/ chloride) 3 
16q13 The  SLC12A3 gene encodes a thiazide 
- sensitive Na+ - Cl- cotransporter that 
mediates reabsorption of Na+ and of Cl- 
at the renal distal convoluted tubule 
ELMO1 Engulfment and cell 
motility 1 
7p14.1 ELMO1 contributes to glomerular 
injury through dysregulation of  the 
ECM metabolism and reduction in cell- 
adhesive properties to ECMs 
ICAM-1* Intracellular 
adhesion molecule 
19p13 Increased ICAM- 1 expression 
accompanies progression of type 1 
diabetes and diabetic nephropathy 
VEGF* Vascular endothelial 
growth factor 
6p12 VEGF expression increased in 
glomeruli of diabetic animals; anti- 
VEGF therapy reduced AER and 
hyperfiltration. 
MBL2* 
 
 
 
 
SUMO4* 
Mannose- binding 
lectin  
 
 
 
Small ubiquitin – 
like modifier 4 
10q11.2-
q21 
 
 
 
6q25 
The MBL pathway of complement 
activation may contribute to the 
development of diabetic microvascular 
complications 
 
SUMO mRNA is mainly expressed in 
kidneys and immune system.  
TNF α* Tumor necrosis 
factor α 
6p21.3 The level of expression of TNF α 
correlated with obesity and  
hyperinsulinemia. 
TGF-β* Transforming 
growth factor – β 1  
19q13.1 TGF-β mRNA and proteins ( and TGF- 
β receptor mRNA) identified in rodent 
glomerular cells.   
MCP-1* Monocyte 
chemotactic protein - 
1 
17q11.2-
q12 
MCP- 1 is produced in response to 
proinflammatory stimuli and high 
glucose level in mesangial cells. 
*Common genetic determinants for the development of type 1 diabetes and diabetic 
nephropathy. 
 
ECM – Extra Cellular Matrix,  AER  -  Albumin Excretion Rate 
 
STAGES OF DIABETIC NEPHROPATHY 
 
 Stage 1 (Very early diabetes) 
  Increased demand upon the kidneys is indicated by an above normal 
GFR. 
Stage 2 (Developing diabetes) 
 The GFR remains elevated or has returned to normal, but glomerular 
damage has progressed to significant microalbuminuria.  
 30 mg of albumin in the urine over a 24-hour period . 
  Without specific interventions 80% of subjects who develop sustained 
microalbuminuria have their urinary albumin excretion increased at a rate 
of  10–20% per year to the stage of overt nephropathy or clinical 
albuminuria  over a period of 10–15 years 
Stage 3 (Overt or dipstick-positive diabetes)  
 Glomerular damage has progressed to clinical albuminuria. 
 The urine is “dipstick positive”.  
 more than 300 mg of albumin in a 24-hour period. 
 Hypertension typically develops during this stage 
 Once overt nephropathy occurs, without specific interventions the 
glomerular filtration rate (GFR) gradually falls over a period of several 
years at a rate that is highly variable from individual to individual (2 to 20 
ml / min/ each year). 
  ESRD develops in 50% of individuals with overt nephropathy within 10 
years and in >75% by 20 years 
Stage 4 (Late stage diabetes). 
  The kidney’s  filtering ability has begun to decline steadily. 
  Blood urea nitrogen (BUN) and creatinine (Cr) has begun to increase.  
 The glomerular filtration rate (GFR) decreases about 10% annually.  
 Almost all patients have hypertension at stage 4. 
Stage 5 (End stage renal disease, ESRD) 
  GFR has fallen to approximately 10 milliliters per minute (<10 ml/min).  
 Renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, kidney 
transplantation) is needed.  
SCREENING AND DIAGNOSIS 
              The American Diabetes Association (ADA) recommends  yearly  
screening for those with type 1 diabetes after 5 yr duration of disease (but not 
before puberty)(64). However, the prevalence of microalbuminuria before 5 years 
in this group can reach 18%, especially in patients with poor glycemic and lipid 
control and high normal blood pressure levels (65). Furthermore, puberty is an 
independent risk factor for microalbuminuria(66). Therefore, in type 1 diabetes, 
screening for microalbuminuria might be performed 1 year after diabetes 
diagnosis, especially in patients with poor metabolic control and after the onset 
of puberty. If microalbuminuria is absent, the screening must be repeated 
annually for both type 1 and 2 diabetic patients (64). However , the Nelson 
Textbook of Pediatrics recommends screening for microalbuminuria after 5 yrs 
duration in prepubertal children and after 2 yrs in pubertal children. 
               The first step in the screening and diagnosis of diabetic nephropathy is 
to measure albumin in a spot urine sample  collected either as the first urine in 
the morning or at random, for example, at the medical visit. This method is 
accurate, easy to perform  and recommended by American Diabetes Association 
guidelines(64). Twenty four-hour and timed urine collections are cumbersome 
and prone to errors related to collecting samples or recording of time. The 
results of albumin measurements in spot collections may be expressed as 
urinary albumin concentration (mg/l)(67,68) or as urinary albumin-to-creatinine 
ratio (mg/g or mg/mmol)(64,68,69,70). Although expressing the results as albumin 
concentration might be influenced by dilution/concentration of the urine sample, 
this option is still accurate and cheaper than expression as albumin-to-creatinine 
ratio(67). The cutoff  value of 17 mg/l in a random urine specimen had a 
sensitivity of 100% and a specificity of 80% for the diagnosis of 
microalbuminuria when 24-hr  timed urine collection was the reference 
standard(71). This value is similar to the cutoff value of 20 mg/l recommended by 
the European Diabetes Policy Group. 
               Screening should not be performed in the presence of conditions that 
increase  urine albumin excretion  such as urinary tract infection, hematuria, 
acute febrile illness, vigorous exercise, short-term pronounced hyperglycemia, 
uncontrolled hypertension, and heart failure (72). Samples must be refrigerated if 
they are to be used the same day or the next day and one freeze is acceptable 
before measurements (69,70). Immunoassays routinely used for albumin 
measurements present adequate diagnostic sensitivity for detection of diabetic 
nephropathy. 
           Although the measurement of urine albumin excretion  is the cornerstone 
for the diagnosis of diabetic nephropathy, there are some patients with  type 1 
diabetes who have decreased glomerular filtration rate (GFR) in the presence of 
normal urine albumin excretion (73,74) and this phenomenon seems to be more 
common among female patients with longstanding diabetes, hypertension and/or 
retinopathy (73). Although renal biopsy was not performed, this observation was 
probably related to renal parenchymal disease other than classical diabetic 
glomerulosclerosis. These studies indicate that normoalbuminuria does not 
protect from a decrease in GFR in type 1 and type 2 diabetic patients. Therefore, 
GFR should be routinely estimated and urine albumin excretion  routinely 
measured for a proper screening of diabetic nephropathy. 
RISK FACTORS 
Diabetic nephropathy develops in, at most  40% of patients with diabetes, 
even when high glucose levels are maintained for long periods of time. This 
observation raised the concept that a subset of patients have an increased 
susceptibility to diabetic nephropathy. Furthermore, epidemiological(75) and 
familial studies(76–80) have demonstrated that genetic susceptibility contributes to 
the development of diabetic nephropathy in patients with both type 1 and type 2 
diabetes. The main potentially modifiable diabetic nephropathy initiation and 
progression factors in susceptible individuals are  dietary factors and sustained 
hyperglycemia(81,82), hypertension(83-85), glomerular hyperfiltration (86-88), 
smoking (89,90), dyslipidemia (83,91,92) and  proteinuria levels (93,94). 
 
PREVENTION AND TREATMENT 
PREVENTION: Normoalbuminuric patients 
The basis for the prevention of diabetic nephropathy is the treatment of its 
known risk factors: hyperglycemia,hypertension, smoking, and dyslipidemia. 
These are also risk factors for cardiovascular disease and should be vigorously 
treated.  
Intensive blood glucose control: 
Clinical trials have consistently demonstrated that A1c levels <7% are 
associated with decreased risk for clinical and structural manifestations of 
diabetic nephropathy in type 1 diabetic patients. In the Diabetes Control and 
Complications Trial (DCCT), intensive treatment of diabetes reduced the 
incidence of microalbuminuria by 39% (94-a). It is interesting to note that patients 
randomized to strict glycemic control had a long-lasting reduction of ׽40% in 
the risk for development of microalbuminuria and hypertension 7–8 years after 
the end of the DCCT(94-b). In the UK Prospective Diabetes Study (UKPDS), a 
30% risk reduction for the development of microalbuminuria was observed in 
the group intensively treated for hyperglycemia(94-c). Moreover, in the 
Kumamoto Study, intensive glycemic control also reduced the rate of 
development of micro and macroalbuminuria(94-d). Therefore, intensive 
treatment of glycemia aiming at A1c <7% should be pursued as early as 
possible to prevent the development of microalbuminuria. 
Intensive blood pressure control:  
Treatment of hypertension dramatically reduces the risk of cardiovascular 
and microvascular events in patients with diabetes. Hypertension is common in 
diabetic patients, even when renal involvement is not present. About 40% of 
type 1 patients with normoalbuminuria have blood pressure levels >140/90 
mmHg(94-d-1). In the UKPDS, a reduction from 154 to 144 mmHg on systolic 
blood pressure reduced the risk for the development of microalbuminuria by 
29% (94-d-2). 
Renin-angiotensin system blockade: 
The role of ACE inhibitors in the prevention of diabetic nephropathy in 
patients with type 1 diabetes has not been defined. 
PREVENTION : Microalbuminuric patients  
Intensive blood glucose control: 
The effect of strict glycemic control on the progression from micro- to 
macroalbuminuria and on the rate of renal function decline in macroalbuminuric 
patients is still controversial. In the DCCT study, intensified glycemic control 
did not decrease the rate of progression to macroalbuminuria in patients with 
type 1 diabetes who were microalbuminuric at the beginning of the study(94-a,94-
e). The Microalbuminuria Collaborative Study Group reported similar   
findings(94-f). However, these studies (94-e,f) were underpowered to detect an 
effect of intensified glycemic control on the progression from micro  to 
macroalbuminuria. Moreover, improvement of glycemic control, especially if 
associated with lower blood pressure levels  reduced the renal function decline 
in proteinuric type 1 diabetic patients (94-g). 
Intensive blood pressure treatment and renin-angiotensin system blockade: 
In microalbuminuric type 1 and type 2 diabetic patients, numerous studies 
have demonstrated that treatment of hypertension  irrespective of the agent 
used, produced a beneficial effect on albuminuria (94-h). Renin-angiotensin 
system (RAS) blockade with Angiotensin converting enzyme (ACE) inhibitors 
or Angiotensin receptor blockers (ARBs) confers an additional benefit on renal 
function. This renoprotective effect is independent of blood pressure 
reduction(94-h,94-i) and may be related to decreased intraglomerular pressure and 
passage of proteins into the proximal tubule(94-j). These drugs decrease urine 
albumin excretion and the rate of progression from microalbuminuria to more 
advanced stages of diabetic nephropathy. A meta-analysis of 12 trials evaluating 
698 nonhypertensive microalbuminuric type 1 diabetic patients showed that 
treatment with ACE inhibitors decreased the risk of progression to 
macroalbuminuria by 60% and increased the chances of regression to 
normoalbuminuria(94-k). 
Dyslipidemia: 
According  to American diabetes association  in its panel conducted in 
2002, drug therapy  has been recommended in children >10 years of age if, after 
an adequate trial of dietary therapy, LDL levels remain ≥190 mg/dl in those 
with no CVD risk factors or >160 mg/dl in those with CVD risk factors(94-l,94-m). 
The goal LDL cholesterol is <130 mg/dl for children in general and <100 mg/dl 
in those with diabetes . Based on the above considerations, the panel 
recommends the following for children and adolescents with lipid values greater 
than the optimal levels as noted above. Blood glucose control should be 
maximized and dietary counseling should be provided. Dietary change has been 
documented to reduce LDL levels(94-n). The use of products such as Benachol 
margarine and increasing amounts of soluble fiber should be considered as part 
of the dietary approach. Follow-up fasting lipid profiles should be performed at 
3 months and then at 6 months to determine the effects of blood glucose 
management and dietary change. If treatment goals are achieved, the lipid 
profile should be repeated yearly. If after 6 months of optimized blood glucose 
control and dietary intervention there is no significant improvement in lipid 
parameters, further intervention is warranted based on LDL levels shown below:  
 LDL 100–129 mg/dl: maximize nonpharmacologic treatment. 
 LDL 130–159 mg/dl: “consider” medication, basing the treatment 
decision on the child’s complete CVD risk profile, including 
assessment of blood pressure and family history.  
 LDL ≥160 mg/dl: begin medication. 
              Resins (bile acid sequestrants) continue to be generally recommended 
as first-choice treatments in this age group. However, compliance rates with this 
class of medications are so low that therapeutic efficacy is lacking. Therefore, 
statin drugs are considered(94-o,94 p).When statins are used, treatment should begin 
at the lowest available dose and dose increases should be based on LDL levels 
and side effects.   
Elevated triglyceride levels are not directly managed with medication. If 
the tryglyceride level is ≥150 mg/dl, efforts are made to maximize blood 
glucose control and achieve desirable weight. If triglycerides are ≥1,000 mg/dl, 
significantly increased risk of pancreatitis is present and treatment with a fibric 
acid medication should be considered.  
Multifactorial intervention: 
Patients with microalbuminuria frequently have other cardiovascular risk 
factors  such as hypertension and dyslipidemia. The multifactorial intervention 
consisted of a stepwise implementation of lifestyle changes and 
pharmacological therapy  including a low-fat diet, a three to five times a week 
of  good exercise program, a smoking cessation program and prescription of 
ACE inhibitors or ARBs and aspirin. 
                In the last few years, we have witnessed enormous progress in the 
understanding of the risk factors and mechanisms of diabetic nephropathy, the 
stages of renal involvement in diabetes  and the treatment strategies to prevent 
or interrupt the progression of diabetic nephropathy. Early detection of diabetic 
nephropathy, adoption of multifactorial interventions targeting the main risk 
factors (hyperglycemia, hypertension, dyslipidemia) and use of agents with a 
renoprotective effect (ACE inhibitors and/or ARBs) do indeed reduce the 
progression of renal disease. Attention to these procedures will also ensure the 
reduction of cardiovascular mortality. 
           
         
AIMS AND OBJECTIVES OF THE STUDY 
1. To estimate the prevalence of microalbuminuria in type 1 diabetic 
patients ≤ 18 yrs of age attending diabetology clinic, Govt Rajaji 
Hospital, Madurai. 
2. To study the associated risk factors in the development of 
microalbuminuria. 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
This study was conducted at Government Rajaji Hospital,Madurai 
Medical College,Madurai. 
Study Type: 
      Observational study 
Duration of the study: 
      August 2010 to November 2011 
Study Population: 
       Type 1 Diabetes mellitus patients of age ≤ 18 yrs of age attending 
Diabetology Clinic at  Govt Rajaji Hospital, Madurai. 
Selection of cases: 
       All cases who are regularly attending diabetology OP and those who are 
willing to participate in this study. 
Inclusion criteria: 
       Onset of type 1 diabetes  ≤  18 yrs 
 Exclusion criteria: 
       1. those with fever 
        2. urine microscopy with  pus cells >10/HPF in uncentrifuged sample 
       3. h/o hematuria  
       4. cases with overt proteinuria 
       5. uncontrollable hypertension. 
Sample size:  
        57 cases 
Study design: 
        57 Type 1 diabetic  patients of age  ≤ 18 yrs attending Diabetology Clinic 
at GRH, Madurai were included in the study after obtaining informed consent. 
Details of name, age, sex, address, age of onset of diabetes, duration of diabetes, 
family h/o and nature of  treatment taken were recorded. Detailed clinical 
examination was done including measurement of blood pressure and BMI.                  
Fasting blood samples were collected for estimation of lipid profile, 
HbA1C, renal parameters and S.calcium. Urine samples collected in sterile 
containers for estimation of microalbuminuria and repeated at 3 months 
intervals, only in positive cases to look for persistence of microalbuminuria. 
HbA1C and microalbuminuria were estimated by immunoturbidimetric method 
and lipid profile by enzymatic method. 
X-ray, ECG and ECHO were taken for all cases. USG  abdomen was 
taken for microalbuminuria positive cases only. Ophthalmological evaluation 
for diabetic retinopathy was done in all cases. 
Ethical clearance: 
 Ethical clearance obtained from the Ethical committee, Govt. Rajaji 
Hospital and Madurai Medical College, Madurai. 
Definition of variables:  
Normal values for biochemical investigations done in this study are, 
Microalbuminuria    -    < 20 mg/l 
HbA1C          -   ≤ 7% 
         Total cholesterol    -  <190 mg%  
         HDLcholesterol     -  >20 mg% 
         LDLcholesterol    -  <130 mg% 
         Triglycerides    -   <150mg%  
Reference values for lipid profile in Indian children were taken from cut   off 
values suggested in Indian Pediatrics Nov 1995. 
      Statistical analysis done by SPSS 17 Statistics software. 
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2. Among the 7 microalbuminuric  cases,  
              No.of.microalbuminuric males       -    2 cases (28.57%) 
              No.of.microalbuminuric females    -    5 cases (71.42%) 
Sex incidence of microalbuminuria 
 
 
The male to female ratio was 1 : 2.5. 
No statistical significance was found with this gender preponderance. 
FAMILY H/O DIABETES: 
23/57 (40.35%) cases had family h/o diabetes mellitus (Type 2). 
3/57 (5.26%) cases had one of their parents as diabetic (Type 2). 
males 
28.57%
females
71.42%
20/57 (35.08%) cases had one of family members (other than 1st degree 
relatives) to be a diabetic. 
DKA EPISODES: 
22/57 (38.5%) cases had h/o ICU admission for DKA 
HYPOGLYCEMIC EPISODES: 
Almost all cases had h/o suggestive of hypoglycemic episodes (blood sugar 
values not documented) 
AGEWISE DISTRIBUTION OF TYPE 1 DIABETES IN THE STUDY: 
          AGE  GROUP              NO. OF DIABETICS 
                       1 - 5                                                       NIL 
                       6-10                             7 
                     11 – 15                           27 
                     16 – 18                           23 
 
AGE GROUP NO OF DIABETICS 
< 12 yrs 12 
>12  yrs 45 
                        Minimum age                 -          7 yrs 
                        Maximum age                -         18 yrs 
                        Mean age                       -         14.32 ± 2.929 yrs  
MEAN AGE NORMOALBUMINURICS MICROALBUMINURICS
Minimum age 7 yrs 14 yrs 
Maximum age 18 yrs 18 yrs 
Mean age 14.10 ± 3.032 yrs 15.86 ± 1.345 yrs 
 
No significant relation was found between mean age in normoalbuminurics and 
microalbuminurics. 
AGE OF ONSET OF TYPE 1 DIABETES: 
Age of onset  ≤ 12 yrs        -     43 cases 
Age of onset  > 12 yrs        -     14 cases 
Minimum age of onset        - 1yr 6months 
Maximum age of onset       -     16 yrs 
Mean age of onset              -     8.965 ± 4.135 yrs 
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DURATION  OF 
DIABETES 
NORMOALBUMINURICS MICROALBUMINURICS
Minimum duration 6 months 3 yrs 
Maximum duration 15.5 yrs 10 yrs 
Mean duration 5.130 ± 3.802 yrs 7.000 ± 3.266 yrs 
 
Though the mean duration of diabetes in microalbuminurics is higher than that 
in normoalbuminurics, it is not statistically significant. 
Among microalbuminurics , 
patients ≤ 5 yrs duration   =  3cases   (42.85%) 
patients > 5yrs duration    =  4cases   (57.15%) 
    -  all cases had HbA1c > 7% 
    -  the earliest period of detection of microalbuminuria was at 3 yrs  of       
       duration of diabetes 
    - Statistical analysis done by tests of significance of proportions between the 
two  groups of duration of diabetes ≤ 5 yrs and > 5 yrs       (Zc = 0.923), 
revealed no significant difference in screening for microalbuminuria in ≤ 5 yrs 
or > 5 yrs   duration of diabetes. 
 
 
 
BODY MASS INDEX: 
4/57 cases had BMI > 95th percentile 
Among the above 4 cases , 2 cases had microalbuminuria. 
Statistical analysis showed significant correlation between high BMI and 
presence of microalbuminuria (p value = 0.02). 
 
HbA1C  : 
 Ranged from  5.7 % - 15.8 % 
                                       ≤ 7%    -      7 cases  ( 12.28%) 
                                       >7%     -      50 cases (87.72%)    
       
 
HbA1C 
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HbA1C NORMOALBUMINURICS MICROALBUMINURICS
Minimum value 5.4 7.7 
Maximum value 15.8 11.4 
Mean value 9.704 ± 2.676 9.543 ± 1.384 
 
No significant correlation exist between HbA1C and microalbuminuria. 
LIPID PROFILE ANALYSIS : 
TOTAL  :    57 patients (30 females & 27 males). 
Total cholesterol ranged from 95mg% to 277mg%. 
HDL ranged from  19 mg% to 47mg%. 
LDL ranged from 42mg%  to 140mg%. 
VLDL ranged from 12mg% to 49mg% and 
Triglycerides ranged from 24mg% to 302mg%. 
 12/57 cases (21 %) had dyslipidemia  
 All the 12 patients had elevated HbA1C ( > 7 %) 
 No dyslipidemia found in patients with normal HbA1C. 
 All dyslipidemic children had hypertriglyceridemia (100%) as the primary    
abnormality. Among these, 
6/12    -  isolated triglyceridemia 
Of the remaining 6 cases with hypertriglyceridemia, 
1/6      -  had decreased HDL 
5/6   -  had increased total cholesterol  
Of the above 5 cases with hypertriglyceridemia and hypercholesterolemia, 
 1/6     -  had increased LDL also 
 
 
Females were affected more than the males  ( 5 males & 7 females ). 
However no statistical significance exist. 
3 cases  (25%) - with duration of diabetes ≤5 yrs   
9 cases  (75%) - with duration of diabetes >5 yrs  
 The minimum duration of diabetes at which dyslipidemia was noted was 
  3 yrs.  
Statistical analysis done between glycemic control ,duration of diabetes and 
lipid profile showed, 
100%
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ABNORMAL LIPID PARAMETERS
1.Positive correlation  between HbA1C and LDL Cholesterol with  p value 
0.007 
 
2. Statistically significant correlation between Hypertriglyceridemia and 
duration of diabetes with p value 0.044  
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3. Significant correlation between VLDL and duration of diabetes  with   p 
value  0.043 
 
 
Microalbuminuria No.of.cases Minimum Maximum Mean 
Std. 
Deviation 
Normo
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nurics 
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TC  50  97  277 144.34 34.667 
HDL  50  20  47 36.24 6.687 
LDL  50  42  140 81.14 23.085 
TRY  50  24  245 119.62 38.306 
TC  7  95  231 147.43 49.047 
HDL  7  19  40 27.71 7.697 
LDL  7  51  120 81.71 22.882 
TRY  7   92  302 160.00 69.785 
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1.The mean Total cholesterol in microalbuminurics (147.43mg%) is 
significantly higher (p value 0.049) than the mean total cholesterol in 
normoalbuminurics (144.34mg%).  
2.The mean HDL cholesterol in microalbuminurics (27.71mg%) is significantly 
lower (p value 0.006) than the mean HDL cholesterol in normoalbuminurics 
(36.24mg%).  
3.Though there was a positive correlation between triglycerides and 
microalbuminuria , it was not statistically significant (p value 0.136). 
4.No significant correlation  was found between LDL cholesterol and 
microalbuminuria .  
    -  3 out of the 12 dyslipidemic cases had microalbuminuria.  
    -  2 of the above 3 cases were found to have microalbuminuria at the  
       shortest duration of diabetes (3 yrs). 
On analysis of the above results , the risk factors for microalbuminuria which 
had statistical correlation in this study were, 
        1. Microalbuminuria and BMI (p value 0.020). 
        2. Microalbuminuria and total cholesterol (p value 0.049). 
        3. Microalbuminuria and High Density Lipoproteins (p value 0.006).  
 
USG ABDOMEN  : 
Bilateral  medical renal disease is found in 2/7 cases of microalbuminuria 
MALES        -        1 case with duration of diabetes  3 yrs      
FEMALES     -       1 case with  duration of diabetes 8 yrs 
RENAL PARAMETERS: 
Blood urea & S.creatinine were normal in all cases . 
S.calcium is within normal limits in all cases 
BLOOD PRESSURE: 
BP is < 95th percentile in all cases 
ECG :  
Found to be within normal limits in all cases 
CHEST X RAY: 
Normal study in all cases. 
ECHO: 
MVP, Trivial MR, Mild diastolic dysfunction were noted in 3 cases 
respectively. All other cases were found to be normal. 
No correlation was found between abnormal cardiovascular function and 
incidence of microalbuminuria. 
 
                                    
 
DISCUSSION 
          The total no of cases enrolled in our study were 57, out of which 30 were 
females and 27 were males. The cumulative prevalence of microalbuminuria in 
our study was 12.28 %. The studies  done  by Jorner et al in  1992, Patel et al in 
1998 and Schaltz et al in 2001 also showed the prevalence of microalbuminuria 
to be 12.50% similar to our study .The  prevalence of microalbuminuria in type 
I diabetic children in different studies ranged between  7% and 28.2%. 
   
Author (Ref No) Year No of Patients Prevalence (%) 
 
Jorner et al.(95)                  1992 351 12.5 
Patel et al. (100) 1998 494 12.5 
Schaltz et al. (103) 2001 494 12.5 
Baak et al. (96) 1993 70 16 
Mathiesen et al. (97) 1995 209 15 
Bruno et al. (98) 1996 211 7 
Jones et al. (99) 1998 233 14.6 
Moore et al. (101)    1999 419 4.29 
MIDAC group(102) 2000 1007 9.7 
Viswanthan et al. (104)   2002 95 28.2 
Moayeri et al (105) 2006 118 19.5 
 
       
The wide range of prevalence in various studies may be due to difference 
in ethnic groups (genetic factors are believed to be responsible for the 
development of diabetic nephropathy), methodology and definition of 
microalbuminuria, population size, length of follow up and mean age of study 
population. 
SEX : 
Male to female ratio in our study is 1 : 2.5 . The higher incidence of 
microalbuminuria in females is also found in other studies – 1 : 1.9 in MIDAC 
and Pittsburg research groups(106,107) confirming that the development of 
microalbuminuria is accelerated in girls. 
 AGE: 
The mean age of the patients with microalbuminuria ( 15.86 yrs ± 1.345) 
was higher than the mean age of the children with normoalbuminuria(14.10 ± 
3.032).  All cases with microalbuminuria were found to be > 12 yrs of age (after 
puberty) in our study. This is comparable with the previous studies which had 
indicated that the onset of microalbuminuria before puberty occurs only rarely 
and consequently screening for microalbuminuria should be recommended for 
children over 12 yrs of age (106-108).There are only a few reports of diabetic 
children who develop diabetic nephropathy in prepubertal period (109,110). 
       On statistical analysis, there was no significant correlation between the 
prevalence of microalbuminuria  and  either  the current age of the patients  or 
age of onset of the disease, similar to the Oxford Regional Prospective study 
(ORPS) cohort (112). 
FAMILY H/O DIABETES: 
        Family history of of type 2 diabetes was present in 40.35% of children. 
5.26% had one of the parents to be a diabetic  and 35.08% had diabetes in the 
family members other than 1st degree relatives. Similar study done in 
Chennai(124)  showed 35% with family h/o type 2 diabetes, 2.9% with one of the 
parents to be diabetic and 27.6% with diabetes in family members. The higher 
percentage of variables noted in this study could be due to smaller sample size 
when compared to the Chennai study which had enrolled 432 children . 
DURATION OF DIABETES: 
          
 The mean duration of diabetes in normoalbuminuric cases was 
5.130±3.802 yrs and in microalbuminuric cases was 7.000±3.266 yrs. Though 
the mean duration of disease in microalbuminuric cases was found to be longer 
than the mean duration in normal subjects, no correlation was found statistically 
(p value > 0.05). Similar reports were found in Oxford Regional Prospective 
study cohort(112)  which included 527 children with the mean duration of 
diabetes of 9.8yrs in both microalbuminurics and normoalbuminurics. 
        The prevalence of microalbuminuria in children with duration of diabetes 
>5 yrs was 17.39% and in ≤ 5 yrs was 8.82%. Among the microalbuminuric 
cases, 42.85%  had duration of diabetes ≤  5 yrs and 57.15%  had  duration > 5 
yrs. In this study, the earliest duration at which microalbuminuria was detected 
was 3 yrs similar to a norway study, which reported  a cumulative prevalence of 
microalbuminuria (12.1%) among Type 1 patients  who had  median diabetes 
duration of 3.0 years(113). Statistical analysis  done by using the tests of 
significance of proportions between the two groups (Zc = 0.923 ), revealed that 
screening of microalbuminuria  in cases with duration of diabetes ≤ 5 yrs  is 
equally significant as that of screening at > 5 yrs duration of disease.As the least 
duration  of diabetes at which microalbuminuria was noted was 3 yrs, this result 
supports the recent consensus for screening of microalbuminuria which  
recommends screening to be done as early as 2yrs after diagnosis in 
postpubertal children and yearly thereafter unlike in prepubertal children where 
screening is done only after 5 yrs of duration of diabetes. 
 
BMI: 
        4 cases were found to have BMI > 95th  percentile indicating obesity, out of 
which 3 were female and 1 was a male. 
         2/4 cases had microalbuminuria. Both of them were females of 16yrs & 
17yrs of age with poor glycemic control of HbA1C 7.7% and 10.3% 
respectively. The duration of diabetes was 10 yrs in both the cases. 
         In our study there was a significant association between BMI and presence 
of microalbuminuria (p value 0.02).This is supported by a London study 
published in 2001 done by Chaturvedi et al(111) which included 1134 cases and 
stated that BMI is an independent baseline risk factor for the incidence of 
microalbuminuria. 
HbA1C: 
      HbA1C ranged from 5.4% to 15.8% in the study population. The mean 
value in normoalbuminuric cases was 9.704% and in microalbuminuric cases 
was 9.543%. There was no significant difference between these two groups 
statistically. Similar report was found in a study done by  Lutale et al(114) as well 
as in ORPS cohort(112) with no significant difference in glycemic control levels 
among normoalbuminuric and microalbuminuric  diabetic patients. These 
studies revealed that despite improvements in glycemic control and numbers of 
subjects achieving HbA1c targets, the prevalence of microalbuminuria was 
unaffected. Collectively these data add further weight to the growing body of 
evidence indicating that factors other than glycemic control may be important in 
the pathogenesis of microalbuminuria during adolescence(115,116). Non-
modifiable predictors of microalbuminuria in childhood include puberty and 
female sex(117), indicating that pubertal hormonal changes occurring in 
adolescents with type 1 diabetes may play a role. Consistent with this 
hypothesis, some experimental and clinical data have implicated changes in the 
growth hormone axis and also sex steroids in the development of pathogenic 
features characteristic of microalbuminuria, namely nephromegaly, glomerular 
hyperfiltration and basement membrane abnormalities (118,119). In contrast to this, 
majority of the studies had revealed significant relation between poor glycemic 
control and microalbuminuria as stated in the review of literature. 
 
LIPID PROFILE: 
In Type I Diabetes Mellitus patients, persistent hyperglycemia increases 
oxidative parameters and hence lipid peroxidation (120,121). This leads to 
dyslipidemia and subsequent cardiovascular morbidity and mortality. 
         The prevalence of dyslipidemia was found to be 21% in the present study 
which is comparable with other studies done in Cambridge (20.1%)(122),spain 
(20%)(123) and Chennai (19%)(124). Hypertriglyceridemia was the primary 
abnormality noted in our study. Similar results were found with studies from 
Chennai which is a close geographical area with comparable food habits.  
There was a strong positive correlation between poor glycemic control 
and LDL cholesterol levels (p value 0.007) in our study. This data agrees with 
those in the literature (125,126).Our study revealed a positive correlation between 
hypertriglyceridemia and duration of diabetes (p value 0.044). This has been 
documented by another study done by Polak et al from Paris(127).  Since VLDL 
is a derived parameter from triglycerides, there was also a significant positive 
correlation between VLDL and duration of diabetes (p value 0.043) in this 
study. 
       The Bogalusa Heart studies and the Pathological determinants of 
atherosclerosis in youth (PDAY study) have clearly concluded that poor 
glycemic control and increase in LDL cholesterol had a strong correlation with 
atherosclerotic plaque in the form of fatty streaks in main carotid artery and 
coronary arteries. The atherosclerotic changes due to dyslipidemia had been 
demonstrated in adolescents as early as 15 years of age in the PDAY study.      
 The minimum duration of diabetes at which dyslipidemia was noted was 
3yrs in our study indicating the need for early screening of dyslipidemia in type 
1 diabetics. 
          3 cases with dyslipidemia had microalbuminuria. 
 
CASE 1 – 15 yrs old  female with 3 yrs of duration of diabetes 
                Had abnormal triglycerides and HDL. 
CASE 2 -  14 yrs old male with 3 yrs of duration of diabetes  
                 Had abnormal triglycerides and total cholesterol. 
CASE 3 - 16 yrs old female  with 10 yrs of duration of diabetes  
                 Had abnormal triglycerides and total cholesterol. 
           The mean value of total cholesterol among microalbuminuric cases 
(147.43 ± 49.047) was significantly higher (p value 0.0449) than among 
normoalbuminuric cases (144.34 ± 34.667). The mean value of HDL cholesterol 
was significantly lower (p value 0.006) in microalbuminuric cases (27.71 ± 
7.697) than normoalbuminuric cases (36.24 ± 6.687). 
         The relationship between microalbuminuria and dyslipidemia has not been 
extensively investigated in young people with type 1 diabetes. With respect to 
the pediatric populations with diabetes, data from the Oxford Regional 
Prospective Study showed that the prevalence of microalbuminuria increased 
across tertiles of total cholesterol(129), supporting our study. Review of literature 
states that, the most consistent association between lipoprotein abnormalities 
and microalbuminuria is the lowering of HDL. The present study also reveals 
the association between microalbuminuria and low HDL as noted in the 
literature.  A recent German study has shown a predictive value of both LDL 
cholesterol and triglycerides on the development of persistent 
microalbuminuria(128). In the present study, no such correlation was found. 
          The above statistical analysis reveals that poor glycemic control leads to 
poor metabolic control  in the form of  dyslipidemia which may hasten the 
development of diabetic nephropathy. 
RENAL PARAMETERS AND BLOOD PRESSURE: 
 
All the cases had normal blood urea, S.creatinine and S.electrolytes. In all 
microalbuminuric positive cases, the GFR was > 90 ml/mt/1.73 sq.m indicating 
stage 2 chronic kidney disease.Blood pressure was < 95th percentile in all cases. 
S.calcium is within normal limits in all cases. This is consistent with the fact 
that presence of microalbuminuria denotes early stage of chronic kidney disease 
with no derangement in renal function. Hence blood pressure was found to be 
normal in all cases as expected  in incipient stage of diabetic nephropathy. As 
hypertention was not noted in any of the cases in this study, correlation could 
not be studied with respect to microalbuminuria. 
ECG: 
In all cases ECG was within normal limits. 
CXR: 
Normal in all cases. 
ECHO: 
3/57 cases showed MVP, Trivial MR and Mild diastolic dysfunction 
respectively. None of the findings were related to diabetic cardiomyopathy. In 
this study, none of the cases had cardiovascular dysfunction and no correlation 
was found between abnormal echo findings and microalbuminuria, glycemic 
control, dyslipidemia and duration of diabetes. According to the study done by 
Bert et al, Belgium(130), predominantly female diabetic children and adolescents  
have significant changes in left ventricular dimensions and myocardial 
relaxation properties as compared with control subjects and seem to be at risk 
for developing diabetic cardiomyopathy  and there was  no correlation with 
HbA1c or diabetes duration similar to our study.  
             In children with type 1 diabetes, endothelial dysfunction is known to 
coincide with microalbuminuria. There are no long-term studies with follow-up 
into late adult life to provide direct estimates of cardiovascular mortality. In 
children with diabetes, progression of urine albumin excretion (even within the 
normal range) starts early and is associated with worse cardiovascular outcomes 
than adults.Hence strict glycemic control , life style modification and ACE 
inhibitors are necessary in these cases in order to prevent the progression to 
cardiovascular disease. 
 
DIABETIC RETINOPATHY: 
                   
           None of the cases had diabetic retinopathy in this study. A study done by 
Donaqhue et al (131), showed incidence of diabetic retinopathy in children > 6 yrs 
of diagnosis to be 24 % along with 2% positive microalbuminuria cases. 
According to ISPAD Clinical Practice Consensus Guidelines 2009 
Compendium, Screening for retinopathy and microalbuminuria should start 
from 11 years with two years diabetes duration and from 9 years with 5 years 
duration. Screening for retinopathy is recommended whenever persistent 
microalbuminuria is confirmed. Hence all microalbuminuric cases  in this study  
are under close follow up for early detection of retinal changes. 
 
                                  
 
 
 
 
CONCLUSION 
 
1. The prevalence  of microalbuminuria among type 1 diabetic patients  was 
12.28%. 
2. 3/7 cases (42.85%) had microalbuminuria within 5 yrs of onset of diabetes. 
3. The least duration of diabetes at which microalbuminuria was noted was 3 
yrs. Screening for microalbuminuria in  ≤ 5 yrs duration was found to be 
statistically significant as that of screening juvenile diabetics of more than 5 
years duration. 
4. Age and gender were not the significant risk factors in the development of 
microalbuminuria statistically. 
5. 50% of patients with BMI > 95th  percentile had microalbuminuria and high 
BMI was found to be a significant risk factor in the development of 
microalbuminuria. 
6. Duration of diabetes was significantly associated with dyslipidemia 
(hypertriglyceridemia). 
7. Poor glycemic control also had strong correlation with dyslipidemia (high 
LDL cholesterol). 
8. Dyslipidemia was found to be significantly associated with 
microalbuminuria. 
a. High total cholesterol and low HDL cholesterol were the significant risk 
factors in the development of microalbuminuria.  Whereas, 
b. Triglycerides and LDL cholesterol did not correlate significantly with the 
development of microalbuminuria. 
9. Dyslipidemic cases in this study were in need of intervention in the form of 
dietary and life style modifications as maximum values were below the 
recommended level for intervention with medications. 
10. Unlike other studies there was no direct correlation between glycemic  
control and microalbuminuria, indicating that there are important factors 
other than glycemic control in the pathogenesis of microalbuminuria like 
genetic susceptibility. 
11. Base line renal parameters and blood pressure were normal in 
microalbuminuric cases similar to normoalbuminuric cases indicating early, 
reversible, incipient stage of diabetic nephropathy. 
12. No evidence of cardiovascular dysfunction/diabetic cardiomyopathy or 
diabetic retinopathy were found in the study group perpetuating the need for 
long term follow up. 
 
 
 
RECOMMENDATIONS 
1. 50%  of  cases with BMI > 95th percentile had microalbuminuria.Hence 
maintenance of desirable weight is necessary among juvenile diabetics. 
2. The juvenile diabetics with dyslipidemia had microalbuminuria within 5 yrs 
of onset of diabetes.Hence screening for microalbuminuria and for its risk 
factors in ≤ 5 yrs duration also is mandatory. 
3. In patients with poor glycemic control,there is a need for early screening for 
dyslipidemia as it is one of the major risk factors in the development of diabetic 
nephropathy. 
4. Early intervention in dyslipidemic cases according to American Diabetes 
Association (ADA) - 2002 panel should be strictly adhered to prevent the 
progression of chronic kidney disease.The recommendations of ADA are,  
A . For LDL cholesterol 
      100-129 mg/dl  -  maximize nonpharmacologic treatment. 
      130-159 mg/dl  -  consider medications if cardiovascular disease risk  
      profile present. 
      >160 mg/dl       -  begin medications with statins. 
B . For Triglycerides 
      ≥150 mg/dl       -  maximize blood glucose control 
                -  achieve desirable weight 
      ≥1000 mg/dl    -  consider fibric acid medications 
5. Long term follow up is recommended to look for cardiovascular dysfunction 
and diabetic retinopathy in microalbuminuric cases. 
6. Since microalbuminuria indicates early and reversible stage of diabetic 
nephropathy, early medical intervention with ACE inhibitors is recommended in 
all microalbuminuric cases as it halts the onset and progression to end stage 
renal disease. 
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PROFORMA 
HISTORY 
•  Name:                            Age:                    Sex:                    Address: 
• Food habits: 
• Age of detection of DM: 
• Duration of symptoms before detection: 
• h/o DM in siblings: 
• h/o DM in parents /family members: 
• h/o any previous viral illness before detection: 
• Associated infection on diagnosis: 
• DKA episodes: 
• Hypoglycemic episodes: 
• Mode of treatment: 
• Duration of treatment: 
CLINICAL EXAMINATION:  
Height:                        weight:                       Head circumference: 
HR:                             RR:                            BP: 
RS:                             CVS:                          P/A:                         CNS: 
 
 
INVESTIGATIONS 
 HbA1C 
 Average blood sugar 
 Microalbuminuria 
 Lipid profile 
 Blood urea 
 S.creatinine 
 S.electrolytes 
 S.calcium 
 Ultrasonogram Abdomen 
 X-ray chest 
 ECG 
 Echocardiogram    
 Ophthalmological evaluation for diabetic retinopathy  (Fundus 
examination) 
           
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
 
M   MALE  
F  FEMALE 
HT   HEIGHT  
WT   WEIGHT  
N   NORMAL  
DM  DIABETIC MELLITUS  
CAL  CALCIUM  
TC  TOTAL CHOLESTEROL 
HDL  HIGH DENSITY LIPOPROTEIN CHOLESTEROL 
LDL  LOW  DENSITY LIPOPROTEIN CHOLESTEROL 
VLDL VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL 
TRY  TRIGLYCERIDES 
 
 
 
